FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Nijhawan Pardeep 		2. Issuer Name and Ticker or Trading Symbol

Edesa Biotech, Inc. [ EDSA ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      __ X __ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
Chief Executive Officer
(Last)          (First)          (Middle)

C/O EDESA BIOTECH INC., 100 SPY COURT 		3. Date of Earliest Transaction (MM/DD/YYYY)

7/26/2019
(Street)

MARKHAM, A6 L3R 5H6
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares   7/26/2019     A    30183   (1) (2) A $0   537312   D    
Common Shares   7/26/2019     A    118345   (1) (2) A $0   2106769   I   Held by Pardeep Nijhawan Medicine Professional Corporation.   (3)
Common Shares   7/26/2019     A    12588   (1) (2) A $0   224094   I   Held by The Digestive Health Clinic Inc.   (3)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)   $2.16   (4) 7/26/2019     A      2667   (3) (5)        (6) 9/26/2027   Common Shares   2667   $0   47490   D    
Stock Option (right to buy)   $2.16   (4) 7/26/2019     A      91   (3) (5)        (7) 12/28/2028   Common Shares   91   $0   1620   D    

Explanation of Responses:
(1)  Represents additional common shares or options to purchase common shares, as applicable, of Edesa Biotech, Inc. (formerly known as Stellar Biotechnologies, Inc.) (the "Issuer") issued pursuant to the post-closing adjustment contemplated by that certain Share Exchange Agreement, dated as of March 7, 2019, by and among the Issuer, Edesa Biotech, Inc. ("Edesa"), and the shareholders of Edesa. The closing of the share exchange transaction contemplated by the Share Exchange Agreement occurred on June 7, 2019, at which time the Issuer acquired all the outstanding capital shares of Edesa from the Edesa shareholders.
(2)  All share numbers and exercise prices reflect the 1-for-6 reverse split of the Issuer's common shares which occurred on June 7, 2019.
(3)  Each of Pardeep Nijhawan Medicine Professional Corporation and The Digestive Health Clinic Inc. are wholly-owned by Pardeep Nijhawan.
(4)  In Canadian currency.
(5)  This option was issued in replacement of an option to purchase shares of Edesa.
(6)  This option vests and becomes exercisable 1/3 on September 26, 2018, and monthly thereafter through September 26, 2020.
(7)  This option vests and becomes exercisable 1/3 on December 28, 2019, and monthly thereafter through December 28, 2021.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Nijhawan Pardeep
C/O EDESA BIOTECH INC.
100 SPY COURT
MARKHAM, A6 L3R 5H6 		X X Chief Executive Officer

Signatures
/s/Pardeep Nijhawan 7/30/2019
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Stellar Biotechnologies Inc. (NASDAQ:SBOT)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025 Stellar Biotechnologies Inc. 차트를 더 보려면 여기를 클릭.
Stellar Biotechnologies Inc. (NASDAQ:SBOT)
과거 데이터 주식 차트
부터 1월(1) 2024 으로 1월(1) 2025 Stellar Biotechnologies Inc. 차트를 더 보려면 여기를 클릭.